Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Levocetirizine in Infants with Allergic Rhinitis or Pruritus
NCT01563081Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levocetirizine in allergic rhinitis (AR) and pruritus, sponsored by GSK. Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) at 2 weeks. Started Apr 2012; status: completed.
02
Drugs
levocetirizine
03
Conditions
allergic rhinitis (AR)pruritus
Beyond the preview
Go deeper on NCT01563081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01563081.